• search
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

WHO ending anti-malaria drug hydroxycholorquine trial for COVID

By PTI
|

Berlin, Juy 05: The World Health Organization says it is ending a trial into whether anti-malaria drug hydroxychloroquine helps patients hospitalised with COVID-19.

WHO ending hydroxycholorquine trial for COVID

WHO said Saturday it has “accepted the recommendation” from the committee overseeing the trial to discontinue testing of hydroxychloroquine and lopinavir/ritonavir, a drug combination used to treat HIV/AIDS.

HIV drug combo found to have no benefit for hospitalised COVID-19 patients in UK trial

The drugs were being compared with standard care for hospitalized patients. WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir “produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care.”

The agency adds that while there was no “solid evidence” of increased mortality for hospitalized patients given the drugs, there were “some associated safety signals in the clinical laboratory findings” of an associated trial.

WHO says the decision won't affect possible trials on patients who aren't hospitalized, or on those receiving the drugs before potential exposure to the coronavirus or shortly afterward.

For Daily Alerts
Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more